$NBI News
Last published 10mo ago
- 10mo agoATAINBIAtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireNEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by
- 10mo agoPBYINBIPuma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)Business WirePuma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday, December 19,
- 10mo agoACRSNBIAclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)GlobeNewswireWAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today
- 10mo agoABVXNBIAbivax to be Added to Nasdaq Biotechnology IndexGlobeNewswireAbivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on
- 10mo agoLFCRNBILifecore Biomedical to be Added to Nasdaq Biotech IndexGlobeNewswireCHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has been
- 11mo agoIMRXNBIImmuneering to be Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is
- 1y agoMESONBIBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®GlobeNewswireNEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational
- 1y agoALVONBIAlvotech Reports Record Results for 2024 and Provides Business UpdateGlobeNewswireTotal Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3
- 1y agoSLDBNBISolid Biosciences Added to the Nasdaq Biotechnology IndexGlobeNewswireCHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 1y agoALVONBIAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024GlobeNewswireAddition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) --
- 1y agoCRMDNBICorMedix Inc. Added to Nasdaq Biotechnology IndexGlobeNewswireBERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
- 1y agoALTIBBNBIAltimmune Added to Nasdaq Biotechnology IndexGlobeNewswireGAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (NASDAQ:NBI)
- 1y agoCLYMNBIClimb Bio to be Added to the Nasdaq Biotechnology IndexGlobeNewswireWELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (NASDAQ:CLYM) today announced that the company will be added to the NASDAQ Biotech Index (NASDAQ:NBI) as part of the annual
- 1y agoSYRENBISpyre Therapeutics Added to the Nasdaq Biotechnology IndexPR NewswireSpyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
- 1y agoMESONBIMesoblast to be Added to Nasdaq Biotechnology IndexGlobeNewswireNEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq
- 1y agoORKANBIOruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireMENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic
- 1y agoCMPSNBICompass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ
- 1y agoZVRANBIZevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024GlobeNewswireCELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases,
- 2y agoSPCEDDOGCRWDGDS+16Baron Global Opportunity Fund | Q2 2026Baron Capital Group
- 2y agoTRMLNBITourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Reached
- 2y agoZYMENBIZymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireReported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics
- 2y agoYMABNBIY-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireRecord DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023;
- 2y agoSVRANBISavara Added to the NASDAQ Biotechnology IndexBusiness WireSavara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (NASDAQ:NBI), effective prior to market
- 2y agoTRMLNBITourmaline Bio added to the NASDAQ Biotechnology IndexGlobeNewswireNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of
- 2y agoZYMENBIZymeworks Added to Nasdaq Biotechnology IndexGlobeNewswireVANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to
- 2y agoAMAMNBIAmbrx to be Added to the NASDAQ Biotechnology Index (NBI)GlobeNewswireSAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ:AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective prior to the market
- 2y agoYMABNBIY-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexGlobeNewswireNEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
- 3y agoIBBTARSNBITarsus Added to NASDAQ Biotechnology IndexGlobeNewswireIRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for
- 4y agoBTXNBIICEBIOBrooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireSAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer
- 4y agoSERANBISERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTSPR NewswireSALT LAKE CITY, March 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announce
- 4y agoERASNBIErasca Reports Fourth Quarter 2021 Financial Results and Business UpdatesGlobeNewswireFive ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459
- 4y agoIPSCNBICentury Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business UpdatesGlobeNewswireIND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence after IND submission Entered into a strategic collaboration with Bristol Myers Squibb to develop
- 4y agoOLMANBIOlema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswirePresented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity in a heavily pretreated patient population Enrollme
- 4y agoQSINBIQuantum-Si Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsBusiness WireFeb. 28, 2022--Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a life sciences company commercializing single molecule protein sequencing, today announced financial results for the fourth quarter and fiscal year ended Decemb
- 4y agoEOLSNBIEvolus Joins Nasdaq Biotechnology IndexBusiness WireCompany Anticipates Strong Finish to 2021 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that its common stock has been selected for inclusion
- 4y agoACHLNBIAchilles Therapeutics Added to the NASDAQ Biotechnology IndexGlobeNewswireLONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Bio
- 4y agoTALSNBITalaris Therapeutics Announces Addition to the Nasdaq Biotechnology IndexGlobeNewswireBOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation
- 4y agoOBSVNBIObsEva Added to the NASDAQ Biotechnology IndexGlobeNewswireGENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced it has been selected for addition to the NA
- 4y agoAQSTIBBNBIAquestive Therapeutics Added to NASDAQ Biotechnology IndexGlobeNewswireWARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic probl
- 4y agoCCCCNBIC4 Therapeutics Added to NASDAQ Biotechnology IndexGlobeNewswireWATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degra
- 4y agoAVIRNBIAtea Pharmaceuticals Added to the Nasdaq Biotechnology IndexGlobeNewswireBOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (NASDAQ:NBI), effective prior to market
- 4y agoIPSCNBICentury Therapeutics Added to the NASDAQ Biotechnology IndexGlobeNewswirePHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for
- 4y agoCMPSNBICOMPASS Selected for Addition to NASDAQ Biotechnology IndexGlobeNewswireLondon, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition t
- 4y agoFBIOIBBMBIONBIMustang Bio Added to the NASDAQ Biotechnology IndexGlobeNewswireWORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematol
- 4y agoVIRXNBIViracta Therapeutics to be Added to the Nasdaq Biotechnology IndexPR NewswireSAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI)
- 4y agoGRCLIBBNBIGracell Biotechnologies Selected for Addition to NASDAQ Biotechnology IndexPR NewswireSUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and aff
- 4y agoIMRXNBIImmuneering Added to the Nasdaq Biotechnology IndexGlobeNewswireCAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling
- 4y agoTKNONBITeknova to Join the Nasdaq Biotechnology IndexGlobeNewswireHOLLISTER, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and
- 4y agoOYSTNBIOyster Point Pharma Announces Addition To Nasdaq Biotechnology IndexGlobeNewswirePRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat oph
- 4y agoSERANBISERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEXPR NewswireSALT LAKE CITY, Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced